Efficacy and toxicity of S-1 in elderly patients with ad vanced non-small lung cancer
- VernacularTitle:替吉奥单药治疗老年晚期非小细胞肺癌疗效及毒性反应观察
- Author:
Li ZHANG
;
Caiqing ZHANG
;
Yonghong QIAN
- Publication Type:Journal Article
- Keywords:
S-1;
NSCLC
- From:
Journal of Chinese Physician
2014;(z2):37-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and toxicity of S -1 monotherapy in elderly patients with advanced non -small lung cancer (NSCLC).Methods Fifty-six patients aged 70 or over with stage IIIb-IV NSCLC were enrolled.S-1 was given orally twice a day according to body surface area on days 1 to 14 for 21-day cycle, the evaluation of efficacy and toxicity were performed on all patients after 2 cycles.Results For all 56 patients, CR 0, PR 15, SD 29 and PD 23 were observed.The objective response rate (ORR) and the disease control rate (DCR) were 26.8% and 78.6%,respectively.The 1-year survival rate was 30.9%, with a medi-an survival of 10.0 months.The myelotoxicity and gastrointestinal toxicity were major side effects .The major toxicity could be tolerated by the patients.Conclusions S-1 monotherapy is an effective chemotherapy for advanced NSCLC in elderly patients with moderate side effects and safety in clinical practice .
